- An EU advisory committee says it won't recommend the authorization of Novartis' (NVS) Serelaxin treatment for acute heart failure.
- The decision is a blow to Novartis, which believes that Serelaxin is a potential blockbuster that could help it overcome the effect of patent expirations.
- Novartis intends to ask the panel to reconsider its view; if it did so, the the Swiss company could start selling the drug in Europe even though a Phase III trial is still continuing. In the U.S., Serelaxin has been designated as a "breakthrough therapy." (PR)
- Meanwhile, the panel has provided a positive opinion of Novartis' Xolair treatment for the skin disease chronic spontaneous urticaria.
EU panel deals blow to Novartis heart drug
Jan 24 2014, 07:07 ET